Literature DB >> 6284396

Treatment of vincristine-induced ileus with sincalide, a cholecystokinin analog.

D V Jackson, W C Wu, C L Spurr.   

Abstract

Sincalide, a synthetic analog of cholecystokinin capable of stimulating bowel motility, has been administered to 12 patients with symptoms and signs of vincristine-induced ileus. Patients were given intravenous infusions of sincalide 0.01 microgram/kg/h over 2-24 h (mean, 8 h) for 1-12 days (mean, 5 days), usually until all evidence of ileus had resolved. Improvement was noted within 48 h of initiation of therapy in eight patients (75%), whereas marginal or no responses were observed in four patients. The mean duration of ileus was 3.6 days in responders and 7.7 days in nonresponders. Toxicity was minimal and consisted of diarrhea in two patients, in whom symptoms promptly resolved with discontinuation of the drug. Further explorations of this promising agent in the treatment of vincristine-induced ileus appears warranted.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284396     DOI: 10.1007/bf00292876

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Vincristine infusion. A phase I study.

Authors:  W Weber; G A Nagel; E Nagel-Studer; R Albrecht
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases.

Authors:  J F Holland; C Scharlau; S Gailani; M J Krant; K B Olson; J Horton; B I Shnider; J J Lynch; A Owens; P P Carbone; J Colsky; D Grob; S P Miller; T C Hall
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

3.  Caerulein treatment for paralytic ileus.

Authors:  A Agosti; G Bertaccini; R Paulucci; E Zanella
Journal:  Lancet       Date:  1971-02-20       Impact factor: 79.321

4.  Vincristine-induced neuropathy. A clinical study of fifty leukemic patients.

Authors:  S G Sandler; W Tobin; E S Henderson
Journal:  Neurology       Date:  1969-04       Impact factor: 9.910

5.  Lactulose in vincristine-induced constipation.

Authors:  A C Harris; J M Jackson
Journal:  Med J Aust       Date:  1977-10-22       Impact factor: 7.738

6.  Intravenous vincristine infusion: phase I trial.

Authors:  D V Jackson; V S Sethi; C L Spurr; V Willard; D R White; F Richards; J J Stuart; H B Muss; M R Cooper; H D Homesley; V W Jobson; M C Castle
Journal:  Cancer       Date:  1981-12-15       Impact factor: 6.860

  6 in total
  3 in total

1.  Prolonged gastrointestinal dysmotility in a patient with hemophagocytic lymphohistiocytosis treated with vincristine.

Authors:  T Tomomasa; R Miyazawa; M Kato; M Hoshino; M Tabata; H Kaneko; M Suzuki; T Kobayashi; A Morikawa
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Effect of vincristine on gastric motility in conscious rats.

Authors:  H Kaneko; T Tomomasa; T Watanabe; A Takahashi; M Tabata; S Hussein; A Morikawa
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat.

Authors:  Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo
Journal:  Front Pharmacol       Date:  2017-02-06       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.